Mednax (MD) Stock Rating Lowered by TheStreet

Mednax (NYSE:MD) was downgraded by equities research analysts at TheStreet from a “b” rating to a “c” rating in a note issued to investors on Monday.

A number of other equities research analysts have also issued reports on the stock. JPMorgan Chase upped their target price on shares of Mednax from $46.00 to $55.00 and gave the company a “neutral” rating in a research note on Monday, February 12th. Zacks Investment Research lowered shares of Mednax from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. BMO Capital Markets upped their target price on shares of Mednax from $46.00 to $58.00 and gave the company a “market perform” rating in a research note on Monday, February 12th. Mizuho restated a “neutral” rating and issued a $53.00 target price (up previously from $49.00) on shares of Mednax in a research note on Friday, February 9th. Finally, Jefferies Group set a $50.00 target price on shares of Mednax and gave the company a “hold” rating in a research note on Tuesday, February 6th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $55.69.

Shares of Mednax stock opened at $51.16 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.18 and a quick ratio of 1.18. Mednax has a twelve month low of $40.56 and a twelve month high of $63.04. The firm has a market cap of $4,771.38, a P/E ratio of 16.24, a price-to-earnings-growth ratio of 1.27 and a beta of 0.23.

Mednax (NYSE:MD) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.04. The company had revenue of $910.82 million during the quarter, compared to analysts’ expectations of $884.55 million. Mednax had a net margin of 9.26% and a return on equity of 10.10%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.00 EPS. sell-side analysts expect that Mednax will post 4 earnings per share for the current year.

In other news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total value of $175,050.00. Following the completion of the transaction, the insider now directly owns 39,716 shares in the company, valued at $2,317,428.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.70% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Earnest Partners LLC boosted its holdings in shares of Mednax by 48.1% in the fourth quarter. Earnest Partners LLC now owns 2,212,691 shares of the company’s stock valued at $118,246,000 after acquiring an additional 718,317 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Mednax by 6.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,515,288 shares of the company’s stock valued at $80,977,000 after acquiring an additional 96,005 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Mednax by 25.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,424,574 shares of the company’s stock valued at $61,428,000 after acquiring an additional 293,011 shares in the last quarter. HealthCor Management L.P. bought a new position in shares of Mednax in the fourth quarter valued at approximately $67,421,000. Finally, Pzena Investment Management LLC bought a new position in shares of Mednax in the fourth quarter valued at approximately $51,411,000. Institutional investors and hedge funds own 98.53% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mednax (MD) Stock Rating Lowered by TheStreet” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/25/mednax-md-stock-rating-lowered-by-thestreet.html.

Mednax Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply